Former Chief Financial Officer · Adaptive Biotechnologies Corp (ADPT)

Chad Cohen

A named executive officer of Adaptive Biotechnologies in every fiscal year CompBrief holds from FY2018 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$72,221

Salary $54,063Stock awards $0

FY2021: $2,911,839

7th of 7 named executive officers at Adaptive Biotechnologies by FY2022 total.

7 named officers on file for Adaptive Biotechnologies, FY2022

Chad Cohen’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • ADPT’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Adaptive Biotechnologies’s whole pay program stands against its peers

  • Adaptive Biotechnologies’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Chad Cohen’s full pay file as a PDF — free

More than this page: up to 10 years of Chad’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Chad Cohen compensation by year

Adaptive Biotechnologies Summary Compensation Table · all 5 fiscal years held
In US dollars, as Adaptive Biotechnologies reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022
Salary$359,188$381,413$411,950$429,375$54,063
Bonus$0$0$0$0$0
Stock awards$0$0$0$899,983$0
Option awards$626,336$554,714$1,703,859$1,377,842$0
Non-equity incentive$158,500$193,900$210,000$200,031$0
Pension and deferred compensation$0$0$0$0$0
All other—$0$3,943$4,608$18,158
Total$1,144,024$1,130,027$2,329,752$2,911,839$72,221

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptive Biotechnologies Corp DEF 14A filed April 28, 2023, accession 0001193125-23-126845, and prior-year filings.

How this page was built: the Adaptive Biotechnologies Corp filed document, accession 0001193125-23-126845. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$1.1M
$1.1M
$2.3M
$2.9M
$72K
FY18
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU20,604$578,148—
Option31,146—$7.27
Option46,042—$31.71
Option51,511—$43.68

Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptive Biotechnologies Corp's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Adaptive Biotechnologies’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Chad RobinsChief Executive Officer$8,853,328
Harlan RobinsChief Scientific Officer$8,459,087
Julie RubinsteinPresident and Chief Operating Officer$6,535,078
Tycho PetersonChief Financial Officer$5,938,257
Sharon BenzenoChief Commercial Officer, Immune Medicine$3,237,784
Kyle PiskelInterim Chief Financial Officer$1,659,147
Chad Cohen · this pageFormer Chief Financial Officer$72,221

The full Adaptive Biotechnologies compensation record

free company brief

This page is one person within Adaptive Biotechnologies's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Adaptive Biotechnologies proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptive Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Chad Cohen's compensation dossier · One-time report. No refunds.